Generate Biomedicines stock jumps as post-IPO lock-up set to expire

Movers Written by: Angela Harmantas 11:10 Tue 25 Aug 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. She earned a Bachelor of... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Generate Biomedicines stock jumps as post-IPO lock-up set to expire Published: 11:10 25 Aug 2026 EDT Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares issued as part of Generate's $400 million initial public offering earlier this year, which included 25 million shares. Lock-up expirations often bring volatility and heavier trading volume as markets absorb a larger pool of tradeable shares. Generate is a clinical-stage generative biology company that combines machine learning, biological engineering and medicine to design new therapeutics. The company's platform pairs computational design with large-scale biological experimentation to create optimized therapies targeting conditions that have historically been difficult or impossible to treat with conventional drug discovery methods. The platform has produced a broad pipeline spanning multiple therapeutic areas and protein-based modalities. Generate, founded in 2018, describes its approach as a shift from drug discovery to drug generation. Continue reading